Truist Financial Issues Pessimistic Forecast for Genmab A/S (NASDAQ:GMAB) Stock Price

Genmab A/S (NASDAQ:GMAB) had its target price reduced by Truist Financial from $50.00 to $45.00 in a research report released on Tuesday morning,Benzinga reports. They currently have a buy rating on the stock.

Several other analysts have also recently commented on the stock. BNP Paribas raised shares of Genmab A/S from a “strong sell” rating to a “hold” rating in a research note on Tuesday, February 11th. Sanford C. Bernstein raised shares of Genmab A/S from a “strong sell” rating to a “hold” rating in a research note on Friday, December 20th. Leerink Partnrs raised shares of Genmab A/S from a “hold” rating to a “strong-buy” rating in a research note on Thursday, February 13th. William Blair raised shares of Genmab A/S from a “market perform” rating to an “outperform” rating in a research note on Tuesday. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $50.00 target price on shares of Genmab A/S in a research note on Thursday, January 23rd. Four investment analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Genmab A/S has an average rating of “Moderate Buy” and an average price target of $41.33.

Genmab A/S Price Performance

Shares of Genmab A/S stock opened at $19.96 on Tuesday. Genmab A/S has a 1 year low of $18.64 and a 1 year high of $31.26. The company has a market capitalization of $13.21 billion, a P/E ratio of 11.47, a P/E/G ratio of 2.65 and a beta of 0.98. The business has a 50 day moving average price of $21.26 and a 200 day moving average price of $22.50.

Genmab A/S (NASDAQ:GMAB) last issued its quarterly earnings data on Wednesday, February 12th. The company reported $0.57 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.28 by $0.29. Genmab A/S had a return on equity of 16.78% and a net margin of 36.30%. As a group, research analysts expect that Genmab A/S will post 1.45 EPS for the current fiscal year.

Institutional Trading of Genmab A/S

Several institutional investors have recently made changes to their positions in the stock. Deep Track Capital LP purchased a new stake in shares of Genmab A/S during the 4th quarter valued at $41,740,000. Renaissance Technologies LLC grew its stake in shares of Genmab A/S by 7.8% during the 4th quarter. Renaissance Technologies LLC now owns 1,926,150 shares of the company’s stock valued at $40,199,000 after buying an additional 139,722 shares during the period. Two Sigma Investments LP boosted its position in Genmab A/S by 122.2% during the 4th quarter. Two Sigma Investments LP now owns 1,706,364 shares of the company’s stock worth $35,612,000 after purchasing an additional 938,455 shares during the period. Two Sigma Advisers LP boosted its position in Genmab A/S by 168.8% during the 4th quarter. Two Sigma Advisers LP now owns 1,653,500 shares of the company’s stock worth $34,509,000 after purchasing an additional 1,038,400 shares during the period. Finally, First Trust Advisors LP boosted its position in Genmab A/S by 18.0% during the 4th quarter. First Trust Advisors LP now owns 1,644,288 shares of the company’s stock worth $34,316,000 after purchasing an additional 251,241 shares during the period. 7.07% of the stock is owned by hedge funds and other institutional investors.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.